ClinicalTrials.gg

Program

SHR-4375

A development code. Also written as “SHR-4375 Injection”.

In Jiangsu HengRui Medicine's pipeline, TF ADC. Its studies are led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jan 2, 20252 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine22 open or runningphase 2since Jan 2, 2025Jan 2, 2025Jan 2027phase 2 · NCT07298772
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-4375, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 2, 2025First study: phase 2 study in Solid TumorsFirst studyNCT06764628 · 208 planned · China
  2. Dec 9, 2025Phase 2 study in Advanced Solid TumorNCT07298772 · 198 planned · China

Ahead

  1. Jan 2027Primary completion: phase 2 study in Advanced Solid TumorNCT07298772
  2. May 2027Primary completion: phase 2 study in Solid TumorsNCT06764628

TargetBeta

“TF ADC”the company's pipeline, read by Claude · source

Other programs on F3

ProgramCompanyFurthest phaseStudies
tisotumab vedotinrulePfizerphase 411
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciencesphase 33
Anti-TF Antibody-drug Conjugate MRG004Arulelepu-biopharma-co-ltdphase 32
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixisphase 11
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rulesutro-biopharma-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07298772Advanced Solid Tumor · China2RecruitingJan 2027198
NCT06764628Solid Tumors · China2RecruitingMay 2027208

How it is read

Names in the registry

  • “SHR-4375 Injection”, 1 entry
  • “SHR-4375”, 1 entry

Codes read as this program: SHR4375.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.